JP2022511866A5 - - Google Patents
Info
- Publication number
- JP2022511866A5 JP2022511866A5 JP2021532219A JP2021532219A JP2022511866A5 JP 2022511866 A5 JP2022511866 A5 JP 2022511866A5 JP 2021532219 A JP2021532219 A JP 2021532219A JP 2021532219 A JP2021532219 A JP 2021532219A JP 2022511866 A5 JP2022511866 A5 JP 2022511866A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- nucleotide
- modified
- rnai construct
- antisense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777677P | 2018-12-10 | 2018-12-10 | |
| US62/777,677 | 2018-12-10 | ||
| PCT/US2019/065294 WO2020123410A1 (en) | 2018-12-10 | 2019-12-09 | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026017347A Division JP2026074186A (ja) | 2018-12-10 | 2026-02-04 | 化学修飾されたＲＮＡｉコンストラクト及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511866A JP2022511866A (ja) | 2022-02-01 |
| JP2022511866A5 true JP2022511866A5 (https=) | 2022-12-14 |
| JP7814932B2 JP7814932B2 (ja) | 2026-02-17 |
Family
ID=69024730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532219A Active JP7814932B2 (ja) | 2018-12-10 | 2019-12-09 | 化学修飾されたＲＮＡｉコンストラクト及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220049252A1 (https=) |
| EP (1) | EP3894554A1 (https=) |
| JP (1) | JP7814932B2 (https=) |
| KR (1) | KR20210102313A (https=) |
| CN (2) | CN113166759B (https=) |
| AU (1) | AU2019395341B2 (https=) |
| BR (1) | BR112021011043A2 (https=) |
| CA (1) | CA3122393A1 (https=) |
| CL (1) | CL2021001490A1 (https=) |
| EA (1) | EA202191630A1 (https=) |
| IL (1) | IL283550A (https=) |
| MX (1) | MX2021006745A (https=) |
| SG (1) | SG11202105900UA (https=) |
| WO (1) | WO2020123410A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019398101B2 (en) | 2018-12-10 | 2025-12-18 | Amgen Inc. | Mutated piggybac transposase |
| MX2022007005A (es) * | 2019-12-09 | 2022-08-25 | Amgen Inc | Construcciones de iarn y metodos para inhibir la expresion de lpa. |
| KR20240004092A (ko) * | 2020-06-01 | 2024-01-11 | 암젠 인크 | Hsd17b13 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법 |
| KR20230046319A (ko) | 2020-08-13 | 2023-04-05 | 암젠 인크 | MARC1 발현을 억제하기 위한 RNAi 작제물 및 방법 |
| AU2021373780A1 (en) * | 2020-11-05 | 2023-06-08 | Amgen Inc. | METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS |
| AU2022212580A1 (en) * | 2021-01-30 | 2023-07-27 | E-Therapeutics Plc | Nucleic acids containing abasic nucleotides |
| EP4294449A1 (en) * | 2021-02-18 | 2023-12-27 | Oneglobe Holdings Limited | Compositions for conjugating oligonucleotides and carbohydrates |
| CA3225054A1 (en) * | 2021-07-08 | 2023-02-12 | Sun Woo Hong | Rnai agent targeting marc1 gene, and use thereof |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| WO2023207615A1 (zh) * | 2022-04-26 | 2023-11-02 | 南京明德新药研发有限公司 | 一类含由天然核苷酸组成突出端的双链RNAi化合物 |
| US20240084301A1 (en) | 2022-07-25 | 2024-03-14 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
| CN120615125A (zh) * | 2022-07-27 | 2025-09-09 | e-生物有限公司 | 核酸化合物 |
| AU2023313030A1 (en) * | 2022-07-27 | 2025-01-09 | E-Therapeutics Plc | Nucleic acid compounds |
| IL319076A (en) * | 2022-09-20 | 2025-04-01 | Shanghai Argo Biopharmaceutical Co Ltd | A defined modified RNAi factor and its composition |
| KR20250088573A (ko) * | 2022-10-14 | 2025-06-17 | 사네진 바이오 유에스에이 인크. | C3을 표적화하는 소형 간섭 rna 및 그의 용도 |
| WO2024140101A1 (zh) * | 2022-12-28 | 2024-07-04 | 北京炫景瑞医药科技有限公司 | 修饰的双链寡核苷酸分子、修饰的双链寡核苷酸缀合物及其用途 |
| TW202509024A (zh) | 2023-05-19 | 2025-03-01 | 大陸商深圳信立泰藥業股份有限公司 | 一種磺醯胺類化合物及其製備方法和醫藥用途 |
| CN119343449A (zh) * | 2023-05-24 | 2025-01-21 | 云合智药（苏州）生物科技有限公司 | 用于抑制angptl3表达的rnai剂及其应用 |
| WO2025113470A1 (en) * | 2023-11-27 | 2025-06-05 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of transthyretin (ttr) |
| WO2025232837A1 (zh) * | 2024-05-08 | 2025-11-13 | 深圳信立泰药业股份有限公司 | 经修饰的siRNA及其制备方法和用途 |
| WO2025260042A1 (en) | 2024-06-14 | 2025-12-18 | Amgen Inc. | Rnai constructs and methods for inhibiting cnr1 expression |
| WO2026002138A1 (zh) * | 2024-06-27 | 2026-01-02 | 成都新泽利医药科技有限公司 | 特定修饰的双链寡核苷酸及其组合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US20120004160A1 (en) * | 2009-02-19 | 2012-01-05 | Glaxo Group Ltd. | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP3564374A1 (en) | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| UY37376A (es) | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
-
2019
- 2019-12-09 WO PCT/US2019/065294 patent/WO2020123410A1/en not_active Ceased
- 2019-12-09 CN CN201980081382.6A patent/CN113166759B/zh active Active
- 2019-12-09 US US17/312,383 patent/US20220049252A1/en active Pending
- 2019-12-09 CA CA3122393A patent/CA3122393A1/en active Pending
- 2019-12-09 KR KR1020217020966A patent/KR20210102313A/ko active Pending
- 2019-12-09 CN CN202410832977.3A patent/CN119061010A/zh active Pending
- 2019-12-09 MX MX2021006745A patent/MX2021006745A/es unknown
- 2019-12-09 JP JP2021532219A patent/JP7814932B2/ja active Active
- 2019-12-09 AU AU2019395341A patent/AU2019395341B2/en active Active
- 2019-12-09 EA EA202191630A patent/EA202191630A1/ru unknown
- 2019-12-09 SG SG11202105900UA patent/SG11202105900UA/en unknown
- 2019-12-09 EP EP19828505.8A patent/EP3894554A1/en active Pending
- 2019-12-09 BR BR112021011043-7A patent/BR112021011043A2/pt unknown
-
2021
- 2021-05-30 IL IL283550A patent/IL283550A/en unknown
- 2021-06-08 CL CL2021001490A patent/CL2021001490A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511866A5 (https=) | ||
| JP2023504744A5 (https=) | ||
| JP2023537943A5 (https=) | ||
| JP6452614B2 (ja) | オリゴヌクレオチドコンジュゲート | |
| JP6060178B2 (ja) | 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法 | |
| JP5952423B2 (ja) | 新規オリゴヌクレオチド接合体およびその用途 | |
| WO2023284763A1 (zh) | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 | |
| US11390867B2 (en) | G-quadruplex-containing antisense oligonucleotides | |
| JP2025532077A (ja) | Ｆｘｉの発現を阻害するためのポリ核酸分子、医薬組成物、およびそれらの使用 | |
| CN117916376A (zh) | 信号可激活核酸复合物 | |
| KR20240099201A (ko) | Pcsk9를 표적화하는 다중핵산 분자 및 이의 용도 | |
| CN118202048A (zh) | 条件可激活核酸复合物 | |
| JP2022550979A5 (https=) | ||
| WO2023284559A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| WO2024137700A2 (en) | Polynucleic acid molecules targeting agt and uses thereof | |
| JP2024537098A5 (https=) | ||
| CN120077134A (zh) | 靶向apoc3的多核酸分子及其用途 | |
| JP2025512771A5 (https=) | ||
| EP4153749A1 (en) | Method for treating cyclophilin a associated diseases | |
| TW202603167A (zh) | 用於抑制ｆｘｉ表現之聚核酸分子、醫藥組合物及其用途 | |
| TW202606726A (zh) | 靶向ａｇｔ之經修飾聚核酸分子及其用途 | |
| WO2024229229A2 (en) | Products and compositions | |
| WO2025264548A2 (en) | Modified polynucleic acid molecules targeting agt and uses thereof | |
| TW202546233A (zh) | 用於抑制ｌｐ（ａ）或ａｐｏｃ３之表現的多核酸分子、醫藥組合物及其用途 | |
| TW202606729A (zh) | 靶向inhbe之聚核酸分子及其用途 |